Cargando…
Editorial Comment: Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Sociedade Brasileira de Urologia
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527099/ https://www.ncbi.nlm.nih.gov/pubmed/32822141 http://dx.doi.org/10.1590/S1677-5538.IBJU.2020.06.09 |
| _version_ | 1783588982200729600 |
|---|---|
| author | Lott, Felipe |
| author_facet | Lott, Felipe |
| author_sort | Lott, Felipe |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7527099 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Sociedade Brasileira de Urologia |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75270992020-10-14 Editorial Comment: Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial Lott, Felipe Int Braz J Urol Update in Urology Sociedade Brasileira de Urologia 2020-09-02 /pmc/articles/PMC7527099/ /pubmed/32822141 http://dx.doi.org/10.1590/S1677-5538.IBJU.2020.06.09 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Update in Urology Lott, Felipe Editorial Comment: Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial |
| title | Editorial Comment: Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial |
| title_full | Editorial Comment: Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial |
| title_fullStr | Editorial Comment: Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial |
| title_full_unstemmed | Editorial Comment: Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial |
| title_short | Editorial Comment: Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial |
| title_sort | editorial comment: ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the hypo-rt-pc randomised, non-inferiority, phase 3 trial |
| topic | Update in Urology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527099/ https://www.ncbi.nlm.nih.gov/pubmed/32822141 http://dx.doi.org/10.1590/S1677-5538.IBJU.2020.06.09 |
| work_keys_str_mv | AT lottfelipe editorialcommentultrahypofractionatedversusconventionallyfractionatedradiotherapyforprostatecancer5yearoutcomesofthehyportpcrandomisednoninferiorityphase3trial |